Background:
The drug levamisole has been successfully used in combination with fluorouracil to increase the disease-free interval and survival of patients who have undergone surgical resection of Dukes' stage C colon cancer. Levamisole is thought to affect the host immune response. Several recent studies have examined its effect on the expression of major histocompatibility complex (MHC) class I molecules, but the results have been inconsistent. An equally important requirement for a host cellular immune response is the adhesion of leukocytes to tumor cells. The latter may be required for cell-mediated antitumor cytotoxic responses. Purpose: We evaluated the ability of levamisole to affect the expression of MHC class I molecules and cell-adhesion molecules and determined whether levamisole could affect leukocyte adhesion to tumor cells that had been treated with the drug. Methods: A panel of four human colon tumor cell lines (HT-29, SW-620, HCT-15, and LoVo), A-375 human melanoma cells, and human umbilical vein endothelial cells (HUVEC) were cultured in the presence of levamisole and examined by solid-phase enzyme immunoassay to determine the level of expression of MHC class I, intercellular adhesion molecule 1 (ICAM-1), vascular cell-adhesion molecule-1 (VCAM-1), leukocyte integrin VLA-4, and lymphocyte-functional antigen (LFA-1) molecules. Adhesion of HL-60 and THP-1 myeloid cells to tumor cells was also evaluated. Tumor necrosis factor (TNF) at 10 ng/mL was used as a positive control for increasing adhesion molecule expression and cell-cell adhesion. The statistical significance of differences in cell surface molecule expression and functional adhesion between treated and control cells were tested by use of analysis of variance and the two-tailed Dunnett's test. Results: Treatment with levamisole (0.1 and 1 |ig/mL) caused the levels of MHC class I expression to increase approximately threefold above control levels on HCT-15 and LoVo colon tumor cells (P<.05 in each case) compared with untreated cells, caused minimal increases on HT-29 cells (to 1.5 times control levels), but caused no significant increases on SW-620 colon tumor or A-375 melanoma cells. The HCT-15 and LoVo colon tumor cells had very low basal MHC expression. Levamisole (1 |ig/mL) increased VCAM-1 expression on HT-29 and SW-620 colon tumor cells to 4.3 and 2.4 times (f<.05 in each case) control levels, respectively, doubled ICAM-1 expression on HT-29 cells (P<.0S), and increased LFA-1 expression on HT-29, LoVo, and A-375 cells to 2.1, 3.2, and 1.8 (P<.05 in each case) times control levels, respectively. TNF (10 ng/mL) was used as a positive control and yielded increased expression of MHC class I molecules on the HT-29, LoVo, SW-620, and HCT-15 cells (2.5, 7.8,1.9, and 4.8 times control levels, respectively; P<.05 in each case). TNF increased VCAM-1 expression to 4.2 times the vehicle-treated control levels (P<.05) on HT-29 cells and increased ICAM-1 expression on HT-29, LoVo, and SW-620 cells (8.4, 1.8, and 1.9 times vehicle control levels, respectively; P<.05 in each case). THP-1 and HL-60 cells demonstrated increased adhesion to levamisole-treated HT-29 colon tumor cells. HL-60 cells also exhibited increased levamisole-mediated adherence to LoVo and HCT-15 cells. Adherence by THP-1 was significantly improved after levamisole treatment of the HUVEC, SW-620, and A-375 cells (P<.05 in each case). Conclusions: Levamisole can directly affect the expression and function of molecules that are engaged in cell-cell recognition and signaling on the surfaces of some tumor cell lines. However, no consistent pattern between cell-adhesion molecule expression, cell-cell adhesion, or levamisole concentration could be discerned. [J Natl Cancer Inst 1996; 88:109-16] Interactions between T lymphocytes (T cells) and accessory cells depend on antigen presentation by accessory cells through recognition of major histocompatibility complex (MHC) molecules. Cytolytic T cells recognize antigen when presented by MHC class I molecules. Similar recognition requirements for T-cell-and macrophage-mediated tumor cell destruction have also been found to occur (J).
Intercellular adhesion molecule-1 (ICAM-1), a member of the immunoglobulin supergene family (2J), is found on lymphocytes and monocytes (4 ,5) and can be induced on endothelial cells by cytokines, such as interleukin I (IL-1), tumor necrosis factor (TNF), and interferon (IFN) (4) (5) (6) . Recognition of and functional binding to ICAM-1 are requirements for successful presentation of antigens to T cells by accessory cells (7) (8) (9) . The counter receptors for ICAM-1 on accessory cells are three heterodimeric proteins of the integrin family consisting of a common beta chain (beta 2 = CD 18) and three different alpha chains (CD1 la, CD1 lb, and CD1 lc) {10-13).
Studies (1, [14] [15] [16] have indicated that ICAM-1 expression on tumor cells may be important for host immune, cell-mediated cytotoxicity. For example, cytokines such as LFN, TNF, and IL-1 are able to increase ICAM-1 expression on tumor cell lines in vitro (e.g., HT-29 human colon tumor cells) and are reported to render the cells susceptible to macrophage-mediated killing (14) . Corecognition of ICAM-1 and MHC class I has also been observed to be a vital factor of host cell-mediated tumor cytotoxicity (/) .
ICAM-1-mediated, cell-adhesive interactions make up only a part of the spectrum of intercellular molecular contacts. For example, vascular cell adhesion molecule-1 (VCAM-1) interactions with its counter receptor (the leukocyte integrin VLA-4 [very late antigen^, also called a4f31 integrin]) (11, 17, 18 ) may be as important as those that depend on ICAM-1. There are reports that mutual recognition of VCAM-1 and VLA-4 between T cells and macrophages is also important in evoking immune responses (11, 18) .
The drug levamisole has been successfully used in combination with fluorouracil (5-FU) to increase the disease-free interval and survival of patients who have undergone surgical resection of Dukes' stage C colon cancer. There is an extensive literature [reviewed in (79)] regarding the ability of levamisole to stimulate the immune system. However, the mechanism by which it operates as an immunoregulator, especially in the context of adjuvant chemotherapy of colon cancer, has not yet been determined. Potential mechanisms that have not been previously examined might involve the expression of adhesion molecules and the functionality of cell-cell adhesion. Several studies (20) (21) (22) of MHC class I expression on tumor cells after levamisole treatment have produced conflicting results. Accordingly, in this study, a panel of human colon tumor cell lines (HT-29, SW-620, HCT-15, and LoVo), A-375 human melanoma cells, and primary human umbilical vein endothelial cells (HUVEC) were examined for changes in MHC and adhesion-molecule expression on their cell surfaces as a function of treatment with levamisole or a TNF-positive control (15, 23) as well as for concomitant effects on the ability of monocytic (THP-1) and promyelocytic (HL-60) cells to adhere to them.
Materials and Methods

Materials
Levamisole was obtained from the Janssen Research Foundation (Beerse, Belgium). The source of 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) was the Pierce Chemical Co. (St. Louis, MO): ABTS was supplied as a solution. Human rccombinant TNF was purchased from Biosource International (Camarillo, CA). Antibodies used for enzyme immunoassay (EIA) studies were purchased from the following sources: HLA-ABC. clone W6/32 (Harlan Bioscience, Indianapolis, IN); ICAM-1 (CD54), clone 8H10 (Immunotech, Westbrook, ME); lymphocyte-functional antigen (LFA-1) (CD 11 a), clone 25.3.1 (Immunotech): VCAM-I, clone 1GI1 (Immunotech); VLA-4 (CDw49d). clone HP2/1 (Immunotech); and goat anti-mouse immunoglobulin G (IgG) Fc fragment-horseradish peroxidase (Jackson Immunoresearch, Media, PA).
Cell Lines
The tumor cell lines used were randomly chosen from a collection of human cell lines available to our laboratory. The HT-29, SW-620, HCT-15, and LoVo colon tumor cell lines were originally obtained from the American Type Culture Collection (ATCC) (Rockville, MD). HCT-15 and SW-620 were derived from patients with Dukes' stage C colon cancer. The Dukes' classification was not determined for the HT-29 and LoVo lines. All four cell lines were low expressors of carcinoembryonic antigen. LoVo and HCT-15 originated from epithelial tumors, HT-29 was derived from a microvillous epithelial tumor, and SW-620 originated from a tumor consisting of round, bipolar cells. The A-375 malignant melanoma cell line was also obtained from the ATCC. Moreover, both the THP-1 monocytic leukemic cell line and the HL-60 promyelogenous leukemia cell lines were obtained from the ATCC. HUVECs were obtained as primary cultures from Clonetics, Inc. (San Diego, CA).
Solid-Phase EIA for Tumor Cell-Surface Molecule Expression
HUVECs were maintained in endothelial cell growth medium (Clonetics, Inc.). Tumor cell lines were maintained in Dulbecco's minimum essential medium with high glucose supplemented with 10% fetal bovine serum, penicillin, streptomycin, and glutamine. Cell culture media and fetal bovine sera were purchased from JRH Biosciences (Lenaxa, KS). For solid-phase EIA, all cells were maintained at subconfluent densities and were plated at 15 000 cells per well into 96-well culture plates 18 hours in advance of any treatment. Complete medium was used for all experiments. For induction of cell-surface adhesion molecules, complete medium was replaced with 200 uX fresh complete medium containing TNF (10 ng/mL) as a positive control, levamisole, or complete medium only. All treatments were in quadruplicate. Cultures were incubated for 48 hours, as described by Webb et al. (14) , washed with phosphate-buffered saline (PBS), pH 7.2, and then analyzed in situ for cell-surface molecule expression Shorter culture times were less than optimal for ICAM-1 expression, consistent with published reports (14, 15) . Twenty microhters of monoclonal antibody (diluted 1:5, 1:10, or 1:20 in PBS containing 0.1% bovine serum albumin) was placed in all wells. Plates were incubated at 4 'C for 4 hours, washed three times with cold PBS, blocked with 100 jiL PBS containing 1% normal goat serum for 30 minutes, and again washed three times with cold PBS. Next, 100 uL of a 1:5000 or 1:10 000 dilution in PBS of purified goat antimouse IgG Fc fragment conjugated to horseradish peroxidase was added to every well. Following a 1-hour incubation at 4 'C, the wells were washed three times with cold PBS, and 150 |iL of ABTS solution was added. Color development was allowed to proceed at 4 'C for 18 hours, except for the A-375 and HCT-15 cell lines that required no more than 1 hour of incubation for ICAM-1 -specific reactions. Color development was quantitated at 405 nm on a 96-well plate reader (Molecular Devices, Inc., Menlo Park, CA). Color development times of 18 hours for A-375 and HCT-15 cell lines yielded optical density readings greater than or equal to 2. Because of the different basal levels of cell-surface molecule expression found for each cell line, combined data are expressed as the percent of control to simplify comparisons between cell lines for changes in cell-surface molecule expression.
Functional Adhesion Bioassay
The adherence of THP-1 monocytic and HL-60 promyelocytic cells as effector cells to a monolayer of target cells was measured. The effector cells were labeled with the fluorescent dye 5-carboxy fluorescein diacetate (Molecular Probes, Eugene, OR) according to the manufacturer's instructions. Target cells were plated in 48-well tissue culture dishes at densities designed to reach confluence by 48 hours. This varied according to the growth rate of the cell line used. During the 48-hour incubation, the cells were grown in control medium, medium containing TNF (10 ng/mL), or levamisole (1 u.g/mL). The cells were then washed twice with PBS, and 5 x 10 3 freshly labeled effector cells in 100 uL PBS were added and incubated at 37 *C for 30 minutes. After being washed with warm PBS (37 'C), adherent cells were quantitated by lysing the culture with 20 uX 1 N NaOH to yield a homogeneous solution for measuring fluorescence with a fluorescent plate reader (Millipore Corp., Bedford, MA). A standard curve of graded numbers of fluorescent effector cells was run with each experiment to calculate the numbers of adherent cells.
Statistics
Each cell line was tested separately for the effect of levamisole on functional cell adhesion or on cell-surface molecule expression as measured by solid-phase EIA. A range of levamisole doses was tested in each experiment and was compared with results obtained from cells treated with vehicle only. TNF (10 ng/mL) as a positive control group was compared against the vehicle control group. In all experiments, levamisole doses overlapped with doses used in previous experiments but may also have included doses not previously tested.
EIA data were normalized to untreated controls. Nonspecific binding was subtracted from all wells, and the ratio of optical density in experimental wells to untreated control wells (E/C) was taken. Mean nonspecific bindings ± standard deviation for the experiments reported herein were as follows: A-375, 0.23 ± 0.04; HCT-15, 0.24 ± 0.07: HT-29, 0.29 ±0.16; LoVo, 0.31 ± 0.08: and SW-620, 0.35 ± 0.03. All functional adhesion data were compared with those obtained with vehicle-treated controls.
A one-factor analysis-of-variance layout with n, treatment groups and one control group was used for both the surface molecule expression (EIA studies) and the functional adhesion studies. Hypotheses tested within cell lines were of the form:
Null: n,-|i r^0 versus alternative: n,-n r £0, where u,, / = 1. ... rip and |i f , respectively, denote the population means for />,-treated groups and the population mean for the control group. The type I error rate of this family of hypotheses was controlled at the 5% level through use of the two-tailed Dunnett's test.
Optical density measurements in EIA studies were re-expressed as a ratio of experimental optical density/control (untreated) optical density to allow comparisons between cell lines with different basal levels of cell-surface molecules. Normality of these data within each cell line was verified through use of the onetailed Shapiro-Wilks test.
Results
MHC Class I Expression on Tumor Cell Lines
Comparisons from a series of experiments with levamisole are shown in Fig. 1 . The four colon tumor cell lines tested expressed low levels of MHC class I, and TNF treatments increased expression 1.5-to 7.5-fold. MHC class I increases on LoVo, HCT-15, and HT-29 cell lines were dependent on levamisole concentration. When incubated with levamisole (0.01-1 ng/mL), MHC class 1 expression in LoVo and HCT-15 was increased to as much as 3.5 and four times vehicle-treated control levels; P<.05. HT-29 cells had a weak response to levamisole (1.5 ± 0.13 times control levels; f<.05) but only with 0.01 ng/mL levamisole. Other levamisole concentrations had no significant effect. In addition, this cell line had low resting-state MHC surface expression. SW-620 did not show increased MHC expression in response to increasing levamisole concentrations; in fact, a decrease occurred with 0.01 (ig/mL levamisole. A-375 malignant melanoma failed to respond to levamisole or TNF with increased MHC class I expression (data not shown).
ICAM-1 Expression on Human Tumor Cell Lines
HT-29 expression of ICAM-1 was increased by 10 ng/mL TNF (Table 1) as reported by Webb et al. (14) . When HT-29 cells were cultured with levamisole, increased ICAM-1 expression was observed for cells treated with 0.1 and 1 (ig/mL. Smaller increases were observed for cells treated with 0.01 and 0.001 |ig/mL, whereas concentrations lower than 0.001 |!g/mL were without effect (data not shown). Maximum average ICAM-1 levels after treatment with 1 (ig/mL levamisole were 2 ±0.18 times (/><.O5) control levels. In contrast to HT-29, the SW-620, LoVo, and HCT-15 cell lines failed to respond to levamisole. SW-620 did respond to TNF, results obtained with LoVo were nonsignificant, and HCT-15 cells failed to respond to TNF. HCT-15 cells, unlike the other three cell lines tested, have extremely high constitutive levels of ICAM-1 expression.
There was no increase in ICAM-1 expression on primary HUVEC or A-375 melanoma cells that had been cultured with levamisole, although both cell lines responded to TNF (2.5-and 
1.9-fold increases, respectively; data not shown). A-375 cells have high constitutive levels of ICAM-1 expression in our studies, and this finding is consistent with published data (14)
for the A-375 cell line.
Other Adhesion Molecules Expressed on Tumor Cells
Data from a series of experiments are shown in Table 1 . Levamisole at 1.0 and 0.1 |0.g/mL caused significant increases in VCAM-1 expression on HT-29 and SW-620 cells (maximum changes were 4.3 ± 0.74 and 2.37 ± 0.70 times vehicle-treated controls; P<.05 in all cases) but had no effect on LoVo, HCT-15, or A-375 cell expression of this molecule. TNF had a stimulatory effect on HT-29 but no effect on the other cell lines.
Levamisole (1 )ig/mL) significantly increased LFA-1 expression on HT-29, LoVo, and A-375 cells to 2.1 ± 0.29, 3.23 ± 0.10, and 1.83 ± 0.37 times vehicle-treated control levels, respectively (f<.05 in each case). LFA-1 was increased more than twofold on HCT-15, but the increase was not statistically significant. The results for low base-line LFA-1 expression on HT-29 and A-375 are consistent with published reports (14) . Neither levamisole nor TNF had significant (P>.05 in all cases) effects on VLA^4 expression on any of the cell lines tested.
Functional Adhesion Studies
In these studies, the binding of HL-60 human promyelocytic cells and THP-1 human monocytic leukemia cells to levamisoletreated target cells was studied (Table 2) .
When compared with vehicle-treated HT-29, adhesion of THP-1 cells to HT-29 cells treated with 1 Ug/mL levamisole was nearly doubled (P<.05), going from 5.1 % ± 0.3% adherence for vehicle-treated cells to 9.8% ± 1.2% adherence after levamisole treatment, with similar increases for HL-60 adhesion (P<.05). Adhesion to HT-29 cells was not affected by levamisole concentrations lower than 0.001 (ig/mL (data not shown). Significant (P<.05) increases in HL-60 adherence (3% ± 0.2% for vehicle-treated cells increasing to a maximum of 9.5% ± 1.3%) occurred in LoVo cells cultured with 0.1 |ig/mL levamisole. Changes in percent adhesion by THP-1 (18.1% ± 0.8% for vehicle-treated cells to a maximum of 23.2% ± 4%) were nonsignificant (P>.05). Treatment of SW-620 cells with levamisole (1 |ig/mL) caused an increase in adhesion by THP-1 cells from 18.6% ± 0.8% to 28.0% ± 2.5% (P<.05) after treatment. Adhesion was improved to 35.8% Blocking experiments (Fig. 2) were performed to ascertain the relative contributions of ICAM-1 and VCAM-1 to adhesion between HT-29 and THP-1 cells. Adhesion to TNF-treated cells appeared to be partly dependent on ICAM-1 (45% inhibition)
but not on VCAM-1. Adhesion to vehicle-treated HT-29 cells could be inhibited 58% and 53% by antibodies to ICAM-1 or VCAM-1, respectively, while adhesion to levamisole-treated HT-29 cells was inhibited 27% and 33% by antibodies to ICAM-1 and VCAM-1, respectively. The fact that this relative percentage is decreased from vehicle-treated control cells implies that there may have been other adhesion molecules affected by levamisole treatment that were not examined in this study. When these antibodies were combined with antibodies to their respective counter receptors, inhibition was not greatly changed (32% for ICAM-1 + LFA-1 antibodies and 35% for VCAM-1 + VLA-4 antibodies). 
Discussion
Our results demonstrate that levamisole can elevate the expression of MHC class I, ICAM-1, VCAM-1, and LFA-1 on certain tumor cell lines. Adhesion by THP-1 and HL-60 cells was increased to those tumor cell lines that demonstrated increased ICAM-1, VCAM-1, and/or LFA-1 as a function of levamisole treatment (Table 3) ; however, except for HT-29 cells, no clear concentration-dependent response for cell-cell adhesion could be discerned. Although adhesion of THP-1 cells to levamisole-treated HT-29 cells appeared to be related to increased ICAM-1, VCAM-1, and LFA-1 levels, no similar general relationships could be discerned for the other cell lines. Concentration-related responses were observed for the effect of levamisole on MHC class I expression on HCT-15 and LoVo cells, for VCAM-1 on SW-620 cells, for LFA-1 expression on LoVo and HCT-15 cells, and for ICAM-1 on HT-29 cells, but no consistent overall relationship between concentration-dependent responses could be discerned for effects on surfacemolecule expression and cell adhesion among all of the cell lines tested. The fact that a relationship could not be found between levamisole doses and the various phenomena examined in this study suggests that 1) there may be different levels of cellassociated receptors or response elements affected by levamisole in the various tumor cell lines tested; 2) other, possibly more relevant, surface molecules were not studied; 3) there may be diversity in the expression of these molecules on rumor cells; and 4) the increased adhesion observed with some cell lines may reflect changes in adhesion-molecule configuration and avidity rather than changes in numbers.
The expression of MHC class I protein was increased on two colon rumor cell lines (HCT-15 and LoVo) to approximately four times the level expressed by vehicle-treated controls and by a smaller amount on HT-29 cells following in vitro levamisole treatment. The functional significance of the observed increases is not clear, since these cell lines had low basal levels of MHC class I expression and the net increases were correspondingly small. These data showing increased MHC expression for some cell lines treated with levamisole conflict with those of other published reports. Goodrich et al. (20) examined CaCo-2 human colon tumor and MDA MB-435 human breast carcinoma cell lines and observed that the expression of MHC class I proteins was decreased after in vitro culture with levamisole. In that study, however, there was no quantitation of MHC expression and the concentration of levamisole (10 u.g/mL) used may not easily be achieved in patients (1924) . However, in the present study, considerably lower concentrations of levamisole were used. Colon tumor cell lines that had low MHC class I expression responded with increases in MHC class I, consistent with small increases seen for WiDr human colorectal cancer cells (22) that express moderate amounts of MHC, while high MHC class I expression by SW-620 cells was generally unaffected by levamisole treatment. The apparent decrease in MHC class I expression observed on SW-620 cells treated with low-dose (0.001 |ig/mL) levamisole is not clearly understood, but it may be a property of cells that have high MHC surface expression. Bellshaped concentration responses (e.g., primary antibody responses) have been observed in the past to occur with levamisole (25) .
In another report, Schiller et al. Reports (127) suggest that increases in MHC class I expression by tumor cells help render those cells susceptible to cytolytic T-cell-or to LAK-mediated cytotoxicity, especially if this is accompanied by high cell-adhesion molecule expression. The increases in MHC class I expression mediated by levamisole, although small in terms of net increases, occurred in three of four colon tumor cell lines tested; in some instances, in- creases in MHC class I expression were accompanied by increases in cell adhesion. The functional significance of these changes in net MHC expression is not clear. Definitive studies to address this aspect of immune-mediated tumor cell killing as a potential result of levamisole treatment have not been performed, and the effect of levamisole on MHC class I expression in vivo is not well established. However, it is worth noting these observations in the context of the reported therapeutic benefit provided by levamisole in the adjuvant treatment of Dukes' stage C colon cancer (28, 29) .
The results reported in this article also demonstrate that levamisole has the ability to directly affect the expression and function of some molecules that are engaged in cell-cell recognition and signaling on the surfaces of some tumor cell lines. Two of the four colon tumor cell lines tested exhibited increased cell adhesion with THP-1 monocytic cells, as did HUVEC. This may reflect an important feature of lymphocyte and antigenpresenting cell interactions resulting from levamisole treatment and may constitute an important aspect of the mechanism of action of levamisole as an immune regulator. Recently, Holcombe et al. (30) reported that levamisole increased the expression of CD56, a marker for natural killer (NK) cell activation. NK cells may recognize tumor targets via ICAM-1 and LFA-1. A report (57) suggests that this recognition may result from intracellular signaling by activated ICAM-1 and LFA-1 and not necessarily only from direct recognition and binding to these molecules.
Treatment of myeloid effector cells with levamisole may also affect adhesion to target cells. Preliminary studies showed that adhesion of THP-1 cells to levamisole-treated HT-29 cells was increased from 9.8% to 11.2% when the THP-1 cells were treated with 1 |ig/mL levamisole (data not shown). In the case of levamisole-treated SW-620 cells, adhesion was increased from 28% ± 2.5% to 44.8% ±7.1% (P<.05) with levamisole-treated THP-1 cells. This result requires further examination. In addition, attempts were made to determine if levamisole-mediated increases in cell adhesion translated into improved cellmediated cytotoxicity. With THP-1 cells, none of the colon tumor cell lines that showed increased adhesion to THP-1 after levamisole treatment were rendered more sensitive to THP-1 -mediated cytotoxicity (Kimball ES: unpublished results). This finding suggests that if the increased adhesion-molecule expression has functional significance, it may not relate to monocytemediated cytotoxicity, but may still relate to antigen presentation and/or T-cell-mediated cytotoxicity.
The alterations in cell-surface molecules studied in this article may only partly explain levamisole-mediated cell-cell interactions as a mechanism of action. The diversity and lack of congruence between in vitro responses reported by us and others (20) (21) (22) 2630 ) for levamisole-treated colon tumor cell lines reflect the fact that still no single mechanism of action can be ascribed to levamisole in the treatment of colon cancer. Increased cell adhesion via levamisole treatments provides a potential mechanism for some of its reported activities as an immune modulator, while increased effector cell recognition of tumor cells via MHC and adhesion molecules provides another hypothetical mechanism for its use as a cancer therapeutic agent.
